Stent coating technology sits at the center of how modern drug-eluting stents prevent the artery from renarrowing after treatment. When a coronary stent is implanted to hold open a narrowed vessel, the metal scaffold alone does the mechanical work of keeping the artery open, but it is the coating layered onto that scaffold that determines how a controlled dose of medication is released into the vessel wall over time. Understanding how these coatings are built, and what distinguishes one polymer category from another, helps explain why coating design remains one of the most closely engineered aspects of coronary stent development.
What Does a Stent Coating Actually Do?
A drug-eluting stent coating serves as a reservoir and delivery vehicle. Rather than releasing all of its medication immediately, a well-designed coating meters out the drug gradually as the vessel heals around the implanted scaffold. This localized delivery approach is intended to reduce the tissue overgrowth response that can lead to restenosis, the renarrowing of a treated artery. The coating must adhere reliably to the metal strut surface through the mechanical stresses of crimping, delivery through tortuous vessels, and balloon expansion, since any loss of coating integrity during these steps could affect how the drug is distributed once the stent is in place.
How Are Stent Coatings Categorized?
In general field terms, coatings on drug-eluting stents are commonly categorized as durable polymer, biodegradable polymer, or polymer-free systems. Durable polymer coatings remain on the stent permanently after the drug has eluted, acting as a stable long-term carrier layer bonded to the metal surface. Biodegradable polymer coatings, by contrast, are engineered to break down gradually over a period of months, with the intent of leaving behind a bare metal stent once drug release is complete. Polymer-free approaches attempt to bind drug directly to a textured metal surface without a separate carrier layer. Each category represents a different engineering approach to the same underlying goal: controlling how much drug reaches the vessel wall and over what timeframe, as established in textbook-level device science across the drug-eluting stent field.
Why Does Coating Integrity Matter During Deployment?
Coating integrity refers to how well the drug-carrying layer stays intact and evenly distributed across the stent surface throughout manufacturing, sterilization, crimping onto the delivery balloon, and the physical stresses of navigating to the lesion site. A coating that cracks, delaminates, or webs between struts during expansion may not deliver medication as intended. This is why coating manufacturing processes typically involve controlled spray or dip application methods, followed by inspection steps designed to confirm uniform thickness and adhesion before a device is released for clinical use. Strut design also plays a role, since thinner struts generally provide a smaller surface area that must be evenly coated while still carrying an effective drug dose.
The ATLAS DES Sirolimus Coating
Among coronary stents built on this general coating science, the ATLAS Drug Eluting Coronary Stent System (Cobalt Chromium) is manufactured with a sirolimus drug coating applied at 1 µg/mm², as reported by the manufacturer. Sirolimus is an established antiproliferative agent used across the drug-eluting stent field to limit the tissue response associated with restenosis. The ATLAS DES platform itself is built on a thin-strut, 60 µm cobalt-chromium L605 alloy scaffold, which the manufacturer describes as supporting durable radial strength and trackability in complex or calcified coronary lesions. This sirolimus dose figure is the specific manufacturer-reported coating detail available for this device; broader statements about coating category or degradation behavior should be understood as general field information rather than device-specific claims.
How Does Coating Design Relate to Restenosis Prevention?
The relationship between coating design and restenosis prevention is a matter of controlled drug delivery over time. Bare metal stents, without a drug coating, rely solely on the mechanical scaffold to hold the vessel open, which historically has been associated with a higher rate of neointimal tissue growth inside the stent. Drug-eluting stent coatings were developed specifically to address this by delivering an antiproliferative agent directly at the treatment site over an extended release window. The choice of polymer category, drug dose, and release kinetics all factor into how a given stent is engineered to balance effective drug delivery against long-term vessel healing. Readers interested in the broader range of coronary devices built on these principles can browse the coronary artery disease and cardiac interventions product category for additional context.
What happens to the coating after the drug has fully released?
This depends on the coating category. Durable polymer coatings remain on the stent as a permanent layer after drug elution is complete, while biodegradable polymer coatings are designed to break down over time, ideally leaving the underlying metal stent in place. Specific degradation behavior and timelines vary by product and should be confirmed through the applicable Instructions for Use (IFU).
Device availability and regulatory status vary by country. Please contact INVAMED or your authorized local distributor for current regulatory information applicable to your region.